Physician profile
Brandon Cottrell
NPI 1679694640
$5,604.46
in general payments reported to CMS, 2019-2025
25 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,359 · 2020: $501 · 2021: $445 · 2022: $70.30 · 2023: $2,070 · 2024: $726 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310 · Travel and Lodging: $802 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.49 |
| Travel and Lodging | $801.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,029.26 | 2019-2025 | Spaceoar Vue System - 10ml, Ams 700, Ams 700 Cxr Rte Kit |
| Medtronic, INC. | $639.40 | 2021-2025 | Interstim |
| Medtronic USA, INC. | $566.09 | 2019-2020 | |
| Teleflex LLC | $512.77 | 2023-2024 | Urolift |
| Sumitomo Pharma America, INC. | $483.91 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $363.88 | 2019-2023 | Myrbetriq |
| Neotract INC. | $185.33 | 2019 | |
| Antares Pharma, INC. | $140.14 | 2019 | |
| Pfizer INC. | $103.08 | 2019-2020 | |
| Urogen Pharma, INC. | $95.28 | 2023-2025 | Jelmyto |
| Coloplast Corp | $84.57 | 2019-2025 | |
| 180 Medical, INC. | $70.22 | 2023-2025 | Gentlecath Glide |
| Endo Pharmaceuticals INC. | $50.42 | 2019 | |
| Ferring Pharmaceuticals INC. | $44.06 | 2024-2025 | Adstiladrin |
| Zyla Life Sciences, INC. | $43.85 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $38.16 | 2019-2020 | |
| Abbvie INC. | $30.00 | 2019 | |
| Axonics, INC. | $22.87 | 2023 | Bulkamid |
| Dendreon Pharmaceuticals LLC | $22.59 | 2025 | Provenge |
| Blue Earth Diagnostics | $15.42 | 2019 | |
| Rochester Medical Corporation | $14.21 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $13.50 | 2019 | |
| Allergan, INC. | $12.16 | 2019 | |
| Olympus America INC. | $11.77 | 2019 | |
| Janssen Biotech, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Cottrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.